Is Transmedics’ (TMDX) Long-Term Growth Potential Still Intact?

23 hours ago 1

Unlock banal picks and a broker-level newsfeed that powers Wall Street.

Soumya Eswaran

Wed, Apr 2, 2025, 5:10 AM 3 min read

Renaissance Investment Management, an concern absorption company, released its Q4 2024 “Small Cap Growth Strategy” capitalist letter. A transcript of the missive tin beryllium downloaded here. The Russell 2000 Growth Index generated a instrumentality of 1.7% successful the 4th quarter, bringing the yearly returns to 15.2%. The portfolio generated affirmative returns successful the 4th fourth and outperformed the Index. The outperformance was driven by banal enactment successful Information Technology and underweight presumption and banal enactment successful Health Care, portion banal enactment successful Communication Services and Consumer Discretionary detracted. For much accusation connected the fund’s champion picks successful 2024, delight cheque its apical 5 holdings.

In its 4th fourth 2024 capitalist letter, Renaissance Investment Management Small Cap Growth Strategy emphasized stocks specified arsenic TransMedics Group, Inc. (NASDAQ:TMDX). TransMedics Group, Inc. (NASDAQ:TMDX) is simply a aesculapian exertion company. The one-month instrumentality of TransMedics Group, Inc. (NASDAQ:TMDX) was 1.23%, and its shares mislaid 9.40% of their worth implicit the past 52 weeks. On April 1, 2025, TransMedics Group, Inc. (NASDAQ:TMDX) banal closed astatine $68.27 per stock with a marketplace capitalization of $2.298 billion.

Renaissance Investment Management Small Cap Growth Strategy stated the pursuing regarding TransMedics Group, Inc. (NASDAQ:TMDX) successful its Q4 2024 capitalist letter:

"TransMedics Group, Inc. (NASDAQ:TMDX) detracted the astir from show successful the 4th arsenic the organ trans works solutions institution reported third-quarter results that were modestly beneath expectations. However, the company’s proprietary organ preservation strategy coupled with its logistics solutions should let important opportunities for market-share summation for a fig of years, and we judge that semipermanent maturation opportunities stay intact.

Is TransMedics Group Inc. (TMDX) the Worst Performing Mid Cap Stock to Buy According to Analysts?

A surgeon successful a modern operating theatre performing a transplant country with aesculapian technology.

TransMedics Group, Inc. (NASDAQ:TMDX) is not connected our database of 30 Most Popular Stocks Among Hedge Funds. As per our database, 29 hedge money portfolios held TransMedics Group, Inc. (NASDAQ:TMDX) astatine the extremity of the 4th fourth compared to 32 successful the 3rd quarter. TransMedics Group, Inc. (NASDAQ:TMDX) reported $121.6 cardinal successful revenues successful the 4th quarter, representing 49.8% year-over-year maturation and 11.8% sequential maturation from Q3 2024. While we admit the imaginable of TransMedics Group, Inc. (NASDAQ:TMDX) arsenic an investment, our condemnation lies successful the content that AI stocks clasp greater committedness for delivering higher returns, and doing truthful wrong a shorter timeframe. If you are looking for an AI banal that is arsenic promising arsenic NVIDIA but that trades astatine little than 5 times its earnings, cheque retired our study astir the cheapest AI stock.

Read Entire Article